105213-30-7

Upstream product

• 67-56-1 methanol 
• 89-98-5 2-chloro-benzaldehyde 
• 65152-40-1 4-(2-chlorophenyl)-2-oxo-3-butenoic acid 

Downstream Products

• 105213-18-1 {3-[(E)-2-(2-Chloro-phenyl)-vinyl]-2-oxo-2H-benzo[1,4]oxazin-6-yl}-acetic acid methyl ester 
• 105213-24-9 2-{3-[(E)-2-(2-Chloro-phenyl)-vinyl]-2-oxo-2H-benzo[1,4]oxazin-6-yl}-propionic acid methyl ester 
• 1228393-36-9 trimethyl 2-(2-chlorophenyl)-4-oxobutane-1,1,4-tricarboxylate 
• 1260498-05-2 methyl 2-(2-benzoyl-3-(2-chlorophenyl)cyclopropyl)-2-oxoacetate 
• 1353676-03-5 (2R,4R)-methyl 4-(2-chlorophenyl)-2-hydroxy-3,4-dihydro-2H-benzo[h]chromene-2-carboxylate 
• 1353676-18-2 (2S,4S)-methyl 4-(2-chlorophenyl)-2-hydroxy-3,4-dihydro-2H-benzo[h]chromene-2-carboxylate 

Relevant academic research and scientific papers

Asymmetric Catalytic Formal 1,4-Allylation of β,γ-Unsaturated α-Ketoesters: Allylboration/Oxy-Cope Rearrangement

A highly enantioselective formal conjugate allyl addition of allylboronic acids to β,γ-unsaturated α-ketoesters has been realized by employing a chiral NiII/N,N′-dioxide complex as the catalyst. This transformation proceeds by an allylboration/oxy-Cope rearrangement sequence, providing a facile and rapid route to γ-allyl-α-ketoesters with moderate to good yields (65–92 %) and excellent ee values (90–99 % ee). The isolation of 1,2-allylboration products provided insight into the mechanism of the subsequent oxy-Cope rearrangement reaction: substrate-induced chiral transfer and a chiral Lewis acid accelerated process. Based on the experimental investigations and DFT calculations, a rare boatlike transition-state model is proposed as the origin of high chirality transfer during the oxy-Cope rearrangement.

4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt effectively increases the LXR transcriptional activity, and therefore can be usefully applied for preventing or treating a dysfunction in cholesterol metabolism, such as cholesterol gallstone, hyperlipidemia, or coronary atherosclerosis.